ADVANCED ENDOMETRIAL CARCINOMA
Clinical trials for ADVANCED ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-stage study tests a combination of two drugs—trastuzumab deruxtecan (DS-8201a) and ceralasertib—in people with advanced solid tumors that have a HER2 mutation. The first part finds the safest dose and checks side effects. The second part compares the combo to DS-8201a …
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug (BAY 1895344) combined with standard chemotherapy for people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, ovarian,…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug combo targets returned ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC